VRDN (Viridian Therapeutics) NonCurrent Deferred Revenue: $113.64 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRDN Viridian Therapeutics Inc VRDN
49 GF Score
Price $23.68
! 5 Warning Signs
View Full Analysis

What is Viridian Therapeutics NonCurrent Deferred Revenue?

Viridian Therapeutics VRDN +2.56% 49 NonCurrent Deferred Revenue is $113.64 Mil as of Jun. 2026. GuruFocus rates VRDN with a GF Score™ of 49/100. The stock has 5 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Viridian Therapeutics's non-current deferred revenue for the quarter that ended in Jun. 2026 was $113.64 Mil.

Viridian Therapeutics NonCurrent Deferred Revenue Related Terms

Viridian Therapeutics NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Viridian Therapeutics's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viridian Therapeutics NonCurrent Deferred Revenue Chart

Viridian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.15 0.86 0.57 0.00 34.24

Viridian Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.00 34.24 36.09 113.64
VRDN
49GF Score
Viridian Therapeutics Inc VRDN
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $113.64 Mil mean?
Viridian Therapeutics (VRDN) has a NonCurrent Deferred Revenue of $113.64 Mil as of Jun. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Viridian Therapeutics and its competitors.
Is Viridian Therapeutics' NonCurrent Deferred Revenue too high?
Viridian Therapeutics' current NonCurrent Deferred Revenue is $113.64 Mil. Overall, Viridian Therapeutics has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' NonCurrent Deferred Revenue compare to BHVN and AGIO?
Viridian Therapeutics' NonCurrent Deferred Revenue of $113.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Biotechnology company?
A good NonCurrent Deferred Revenue depends on the Biotechnology industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Viridian Therapeutics and its competitors. Viridian Therapeutics's current NonCurrent Deferred Revenue is $113.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Viridian Therapeutics (VRDN) has a current NonCurrent Deferred Revenue of $113.64 Mil. The current NonCurrent Deferred Revenue is $113.64 Mil. Viridian Therapeutics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Viridian Therapeutics (VRDN), the current NonCurrent Deferred Revenue is $113.64 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viridian Therapeutics Business Description

Other Exchanges 0K1R:UK1S1:Germany
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
49GF Score

Get the complete analysis for VRDN

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.68
Price